 WARMER, Pa., Oct. 21, 2021 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus HBV infection and to treat coronaviruses including COVID-19, today announced that it has scheduled its third quarter 2021 financial results and corporate update for Thursday, November 4, 2021. The schedule for the press release and conference callwebcast are as follows: 